


Ask a doctor about a prescription for ROPIVACAINE KABI 2 mg/ml SOLUTION FOR INFUSION
Package Leaflet: Information for the User
Ropivacaína Kabi 2 mg/ml solution for infusion EFG
Ropivacaína, hydrochloride
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
The name of this medicine is “Ropivacaína Kabi 2 mg/ml solution for infusion EFG”, but in the rest of this leaflet it will be called “Ropivacaína Kabi”.
Contents of the pack:
Ropivacaína Kabi 2 mg/ml solution for infusion is indicated in adults and children of all ages for the treatment of acute pain. It numbs (anesthetizes) parts of the body, e.g., after surgery.
You will not be given Ropivacaína Kabi
If you are not sure if any of the above applies to you, talk to your doctor before you are given Ropivacaína Kabi.
Warnings and precautions
Special care should be taken to avoid any injectionof Ropivacaína Kabi directly into the bloodstreamto prevent any immediate toxic effects. It should not be injected into inflamed areas.
Tell your doctor, nurse or any other healthcare professional before you are given Ropivacaína Kabi:
Tell your doctor if you have any of these problems, as it may be necessary to adjust the dose of Ropivacaína Kabi.
Tell your doctor, nurse or any other healthcare professional before you are given Ropivacaína Kabi:
Tell your doctor if you or a family member has porphyria, as it may be necessary to use another anesthetic.
Tell your doctor about any illness or medical condition you have before starting treatment.
Children
Special care should be taken:
Using Ropivacaína Kabi with other medicines
Tell your doctor or healthcare professional that you are using, have recently used or may need to use any other medicine. This is because Ropivacaína Kabi may affect how some medicines work, and other medicines may affect Ropivacaína Kabi.
In particular, tell your doctor if you are using any of the following medicines:
Your doctor needs to know this to calculate the correct dose of Ropivacaína Kabi to give you.
Also, tell your doctor if you are using any of the following medicines:
This is because your body takes longer to eliminate Ropivacaína Kabi if you are using these medicines. If you are using any of these medicines, prolonged use of Ropivacaína Kabi should be avoided.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
It is not known if ropivacaína affects pregnancy or if it passes into breast milk.
Ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines
Ropivacaína Kabi may cause drowsiness and affect your reaction speed. Do not drive or use tools or machines after taking Ropivacaína Kabi, until the next day.
Ropivacaína Kabi contains sodium chloride.
This medicine contains 3.4 mg of sodium (main component of table/cooking salt) per milliliter. This is equivalent to 0.17% of the maximum recommended daily sodium intake for an adult.
Ropivacaína Kabi will be given to you by a doctor. The dose that your doctor gives you will depend on the type of pain relief you need. It will also depend on your size, age, and physical condition.
Ropivacaína Kabi will be given to you as an infusion. The part of the body where it will be used will depend on why you are being given Ropivacaína Kabi. Your doctor will give you Ropivacaína Kabi in one of the following places:
When Ropivacaína Kabi is used in one of these ways, it prevents nerves from sending pain messages to the brain. It prevents you from feeling pain, heat, or cold where it is used, however, you may still have other sensations such as pressure or touch.
Your doctor knows the correct way to give you this medicine.
Dosage
The dose used will depend on why you are being given the medicine and your health, age, and weight.
Duration of treatment
The administration of ropivacaína usually lasts between 0.5 and 6 hours, but may last up to 72 hoursin case of pain reliefduring and after surgery.
If you are given more Ropivacaína Kabi than you should
Severe side effects due to the administration of more Ropivacaína Kabi than necessary require special treatment and the doctor treating you is prepared to handle these situations.
The first signs that you have been given too much Ropivacaína Kabi are usually the following:
These symptoms can precede cardiac arrest, respiratory arrest, or severe convulsions.
To reduce the risk of severe side effects, your doctor will stop the administration of Ropivacaína Kabi as soon as these signs appear. This means that if any of these signs occur to you, or if you think you may have received too much Ropivacaína Kabi, tell your doctor or healthcare professional immediately.
More severe side effects from receiving too much Ropivacaína Kabi include problems with speech, muscle stiffness, tremors, agitation, seizures, and loss of consciousness.
Tell your doctor or healthcare professional if you notice any of the above symptoms.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Important side effects to look out for:
Sudden allergic reactionsthat can be life-threatening(such as anaphylaxis, including anaphylactic shock) are rare, affecting between 1 and 10 patients in every 10,000. Possible symptoms include:
If you think you are having an allergic reaction to Ropivacaína Kabi, tell your doctor or healthcare professional immediately.
Other possible side effects:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Anxiety
Decreased skin sensitivity
Fainting
Breathing difficulties
Low body temperature (hypothermia)
Some symptoms may occur if the infusion is given into a blood vessel by mistake, or if you have been given too much Ropivacaína Kabi (see also section 3 “If you are given more Ropivacaína Kabi than you should” above). This includes seizures, dizziness or lightheadedness, numbness of the lips and around the mouth, tongue numbness, hearing problems, vision problems, speech problems, muscle stiffness, and tremors
Rare(may affect up to 1 in 1,000 people)
Frequency not known(cannot be estimated from the available data):
Other possible side effects include:
Possible side effects detected with other local anesthetics that may also be caused by Ropivacaína Kabi include:
Children
In children, the side effects are the same as in adults except for low blood pressure, which occurs less frequently in children (affecting between 1 and 10 children in every 100) and general discomfort, which occurs more frequently in children (affecting more than 1 in 10).
Reporting of side effects:
If you experience any side effects, talk to your doctor or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Monitoring System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep out of sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bag. The expiry date is the last day of the month stated.
Store below 30°C.
Do not use this medicine if you notice a precipitate in the solution for infusion.
Normally, your doctor or hospital will store Ropivacaína Kabi and are responsible for the quality of the product once opened if it is not used immediately. They are also responsible for disposing of any unused Ropivacaína Kabi correctly.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Ropivacaína Kabi
Each 200 ml plastic bag contains 400 mg of ropivacaine (hydrochloride).
Appearance of the Product and Container Content
Ropivacaína Kabi solution for infusion is a clear and colorless solution for infusion.
Ropivacaína Kabi 2 mg/ml solution for infusion is available in transparent plastic bags of 100 ml and 200 ml.
Package sizes:
1 bag with overwrap
5 bags with overwrap
10 bags with overwrap
Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Fresenius Kabi España S.A.U.
C/ Marina 16-18
08005 Barcelona
Spain
Manufacturer
HP Halden Pharma AS
Svinesundsveien 80
1788 Halden
Norway
This medicinal product is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
Netherlands | Ropivacaine HCl Fresenius Kabi 2 mg/ml solution for infusion |
Austria | Ropivacaine hydrochloride Kabi 2 mg/ml infusion solution |
Belgium | Ropivacaine Fresenius Kabi 2 mg/ml solution for infusion |
Cyprus | Ropivacaine/Kabi 2 mg/ml, solution for infusion |
Germany | Ropivacaine hydrochloride Kabi 2 mg/ml infusion solution |
Denmark | Ropivacaine Fresenius Kabi, infusion bag, solution, 2 mg/ml |
Estonia | Ropivacaine Kabi |
Greece | Ropivacaine/Kabi 2 mg/ml, solution for infusion |
Spain | Ropivacaine Kabi 2 mg/ml solution for infusion EFG |
Finland | Ropivacaine Fresenius Kabi 2 mg/ml infusion solution, liquid |
France | Ropivacaine Kabi 2 mg/ml, solution for perfusion in bag |
Hungary | Ropivacaine Fresenius Kabi 2 mg/ml solution for infusion |
Italy | Ropivacaine Kabi |
Latvia | Ropivacaine Kabi 2 mg/ml solution for infusion |
Lithuania | Ropivacaine hydrochloride Kabi 2 mg/ml infusion solution |
Luxembourg | Ropivacaine Fresenius Kabi 2 mg/ml infusion solution |
Malta | Ropivacaine Kabi 2 mg/ml |
Norway | Ropivacaine Fresenius Kabi 2 mg/ml infusion solution, liquid |
Poland | Ropivacaine Kabi |
Portugal | Ropivacaine Kabi |
Slovenia | Ropivacaine hydrochloride Kabi 2 mg/ml solution for infusion |
Sweden | Ropivacaine Fresenius Kabi 2 mg/ml, infusion solution, liquid |
United Kingdom (Northern Ireland) | Ropivacaine 2 mg/ml solution for infusion |
Date of the last revision of this leaflet: November 2024
“Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/”
------------------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Handling
Ropivacaína Kabi should only be used by, or under the supervision of, clinical personnel with experience in regional anesthesia (see section 3)
Shelf life after opening: Use immediately.
Ropivacaína Kabi products are intended for single use. Discard any unused solution.
The medicinal product should be visually inspected before use. The solution should only be used if it is clear, practically free of particles, and if the container is not damaged.
The intact container should not be re-autoclaved. A blister pack should be chosen when a sterile environment is required.
Incompatibilities
Compatibility with other solutions, apart from those mentioned below, has not been investigated.
Precipitation may occur in alkaline solutions, as ropivacaine has limited solubility at pH > 6.0.
Compatibility
Ropivacaine solution for infusion in plastic bags for infusion is chemically and physically compatible with the following medicinal products:
Concentration of Ropivacaína Kabi: 1-2 mg/ml | |
Additive | Concentration* |
Fentanyl citrate | 1.0 – 10.0 µg/ml |
Sufentanil citrate | 0.4 – 4.0 µg/ml |
Morphine sulfate | 20.0 – 100.0 µg/ml |
Clonidine hydrochloride | 5.0 – 50 µg/ml |
The mixtures are chemically and physically stable for 30 days at 20 to 30°C. From a microbiological point of view, the mixtures should be used immediately. If not used immediately, the storage and conditions prior to use are the responsibility of the user and are not usually more than 24 hours at 2 – 8°C.
Disposal
Disposal of unused medicinal products and all materials that have come into contact with them should be carried out in accordance with local regulations.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for ROPIVACAINE KABI 2 mg/ml SOLUTION FOR INFUSION – subject to medical assessment and local rules.